Overview
- An FDA Pharmacy Compounding Advisory Committee voted July 23–24 to recommend adding six peptides to the Section 503A bulks list, a step that is advisory only and does not change current law.
- The six peptides named by the committee are BPC‑157, TB‑500, KPV (topical), MOTS‑c, Semax and Epitalon, which supporters say are widely used outside formal trials and sold online as unregulated ‘research’ products.
- Patient‑safety groups and FDA career scientists warned the vote moved forward despite gaps in human data and raised specific risks such as batch contamination, immune reactions to repeated injections, variable product composition, and possible tumor promotion for some growth‑promoting peptides.
- Clinicians and industry advocates argued regulated compounding would channel patients away from an unsafe grey market and allow oversight, dosing guidance and real‑world data collection under licensed prescribers and pharmacies.
- The FDA will now review the committee record, public comments and staff analyses before any formal rulemaking, a process that could take months to a year, and the vote has drawn scrutiny over recent panel changes and disclosed ties that critics say undermine trust.